These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38458305)

  • 1. Influence of zoledronic acid and pamidronate on tooth eruption in children with osteogenesis imperfecta.
    Del Rio Cantero N; Mourelle Martínez MR; Sagastizabal Cardelús B; De Nova García JM
    Bone; 2024 May; 182():117069. PubMed ID: 38458305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of bisphosphonates on tooth eruption in children with osteogenesis imperfecta.
    Kamoun-Goldrat A; Ginisty D; Le Merrer M
    Eur J Oral Sci; 2008 Jun; 116(3):195-8. PubMed ID: 18471236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bisphosphonate Therapy and Tooth Development in Children and Adolescents with Osteogenesis Imperfecta.
    Malmgren B; Tsilingaridis G; Monsef-Johansson N; Qahtani ZHA; Dahllöf G; Åström E
    Calcif Tissue Int; 2020 Aug; 107(2):143-150. PubMed ID: 32451573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cranial base pathology in pediatric osteogenesis imperfecta patients treated with bisphosphonates.
    Arponen H; Vuorimies I; Haukka J; Valta H; Waltimo-Sirén J; Mäkitie O
    J Neurosurg Pediatr; 2015 Mar; 15(3):313-20. PubMed ID: 25559924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Timing of dental development in osteogenesis imperfecta patients with and without bisphosphonate treatment.
    Vuorimies I; Arponen H; Valta H; Tiesalo O; Ekholm M; Ranta H; Evälahti M; Mäkitie O; Waltimo-Sirén J
    Bone; 2017 Jan; 94():29-33. PubMed ID: 27725317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of intravenous zoledronic acid in paediatric osteoporosis.
    Brown JJ; Zacharin MR
    J Pediatr Endocrinol Metab; 2009 Jan; 22(1):55-63. PubMed ID: 19344075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of a 1-year treatment with zoledronic acid compared with pamidronate in children with osteogenesis imperfecta.
    Barros ER; Saraiva GL; de Oliveira TP; Lazaretti-Castro M
    J Pediatr Endocrinol Metab; 2012; 25(5-6):485-91. PubMed ID: 22876543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bisphosphonate therapy for osteogenesis imperfecta.
    Dwan K; Phillipi CA; Steiner RD; Basel D
    Cochrane Database Syst Rev; 2014 Jul; (7):CD005088. PubMed ID: 25054949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bisphosphonate therapy for osteogenesis imperfecta.
    Dwan K; Phillipi CA; Steiner RD; Basel D
    Cochrane Database Syst Rev; 2016 Oct; 10(10):CD005088. PubMed ID: 27760454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of intravenous Zolidronic acid in the treatment of pediatric osteogenesis imperfecta: a systematic review.
    Mahmoud I; Bouden S; Sahli M; Rouached L; Ben Tekaya A; Tekaya R; Saidane O; Abdelmoula L
    J Pediatr Orthop B; 2024 May; 33(3):283-289. PubMed ID: 37339526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous Bisphosphonate Therapy of Young Children With Osteogenesis Imperfecta: Skeletal Findings During Follow Up Throughout the Growing Years.
    Palomo T; Fassier F; Ouellet J; Sato A; Montpetit K; Glorieux FH; Rauch F
    J Bone Miner Res; 2015 Dec; 30(12):2150-7. PubMed ID: 26059976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship of Pathogenic Mutations and Responses to Zoledronic Acid in a Cohort of Osteogenesis Imperfecta Children.
    Sun L; Hu J; Liu J; Zhang Q; Wang O; Jiang Y; Xia W; Xing X; Li M
    J Clin Endocrinol Metab; 2022 Aug; 107(9):2571-2579. PubMed ID: 35727737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osteogenesis Imperfecta: update on presentation and management.
    Cheung MS; Glorieux FH
    Rev Endocr Metab Disord; 2008 Jun; 9(2):153-60. PubMed ID: 18404382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute and long-term effects of zoledronate in adult patients with osteogenesis imperfecta. An observational Spanish study with five years of follow-up.
    Pavón de Paz I; Rosado Sierra JA; Pérez Blanco C; Modroño Móstoles N; Guijarro de Armas G; Navea Aguilera C
    Endocrinol Diabetes Nutr (Engl Ed); 2019 Feb; 66(2):108-116. PubMed ID: 30077631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zoledronic acid in children with osteogenesis imperfecta and Bruck syndrome: a 2-year prospective observational study.
    Otaify GA; Aglan MS; Ibrahim MM; Elnashar M; El Banna RA; Temtamy SA
    Osteoporos Int; 2016 Jan; 27(1):81-92. PubMed ID: 26138583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Efficacy of Zoledronic Acid in children with Osteogenesis Imperfecta.
    Riaz M; Hafeez S; Ibrahim MN; Khoso ZA; Laghari Br TM; Raza SJ
    J Coll Physicians Surg Pak; 2022 Sep; 32(9):1165-1169. PubMed ID: 36089714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Administration of the bisphosphonate zoledronic acid during tooth development inhibits tooth eruption and formation and induces dental abnormalities in rats.
    Hiraga T; Ninomiya T; Hosoya A; Nakamura H
    Calcif Tissue Int; 2010 Jun; 86(6):502-10. PubMed ID: 20411381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pamidronate affects the mandibular cortex of children with osteogenesis imperfecta.
    Apolinário AC; Figueiredo PT; Guimarães AT; Acevedo AC; Castro LC; Paula AP; Paula LM; Melo NS; Leite AF
    J Dent Res; 2015 Mar; 94(3 Suppl):95S-102S. PubMed ID: 25608973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Root resorption of primary molars and dental development of premolars in children with Osteogenesis Imperfecta medicated with bisphosphonates, grouped according to age and gender.
    Garcete Delvalle CS; De Nova García MJ; Mourelle Martínez MR
    BMC Oral Health; 2024 Jul; 24(1):857. PubMed ID: 39069613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment response to long term antiresorptive therapy in osteogenesis imperfecta type VI: does genotype matter?
    Celik NB; Gonc N; Ozon A; Alikasifoglu A; Rauch F; Kandemir N
    J Pediatr Endocrinol Metab; 2020 Dec; 33(12):1617-1624. PubMed ID: 33031053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.